A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Orthofix Medical Announces FDA Clearance and Initial Patient Implant of the Company’s 1st 3D-Printed Titanium Cervical Spacer System with Nanovate Technology

April 5, 2021

Orthofix Medical Inc. today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and the first patient implant of the 3D-printed CONSTRUX Mini Ti Spacer System.

Developed to enhance anterior cervical discectomy and fusion (ACDF) procedures, the CONSTRUX Mini Ti cervical spacer with NanovateTechnology is the first 3D-printed titanium interbody introduced to the market by Orthofix.

“The ACDF procedure, which is often used to treat a herniated cervical disc or degenerative disc disease, involves replacing a patient’s damaged cervical disc with an interbody packed with a biologic to promote fusion in order to provide stability and strength to the area,” said Wayne Cheng, M.D., an orthopedic spine surgeon operating at Loma Linda University Medical Center in Loma Linda, CA, who performed the first patient implant procedure. “The CONSTRUX Mini Ti System’s optimized porosity and surface allows bone to grow into and through the spacer in order to aid with the patient’s fusion.”

The CONSTRUX Mini Ti Spacer System with Nanovate Technology is one of many Orthofix products with nanotechnology FDA clearance including the CONSTRUX Mini PTC Spacer System, the Pillar SA PTC Spacer System, and the FORZA PTC Spacer System. When compared to solid PEEK devices, the 3D-printed endplates of these implants with Nanovate Technology show a significant increase in growth factors involved in osteogenesis and osteoblast maturation resulting in a more favorable osteogenic environment for bone ingrowth.

“Orthofix’s cervical spine offerings feature a wide array of implants ranging from motion-preserving products like the M6-C artificial cervical disc to advanced interbody and fixation solutions that aid surgeons in restoring spinal alignment and decreasing pain and nerve compression,” said Orthofix President of Global Spine Kevin Kenny. “We are dedicated to expanding our comprehensive cervical spine solutions with technologies like the CONSTRUX Mini Ti Spacer System that can make a meaningful difference in our product offerings and in the lives of patients.”

The CONSTRUX Mini Ti Spacer System features include:

  • 3D-printed porous titanium with macro, micro, and nanoscale surface features
  • Nanoscale surface that has been shown to increase proliferation and alkaline phosphatase activity (an early osteogenic differentiation marker) in human stem cells in vitro*
  • Endplates with 400 micron pores and 50-percent porosity designed to help facilitate bone ingrowth**
  • Functional gradient porous structure with 80-percent porosity at the midline of the implant which allows for increased fluoroscopic visualization
  • Large center opening with concaved inner walls for packing bone-grafting material
  • Straightforward instrumentation for easy implantation

Orthofix offers a comprehensive cervical portfolio with differentiated technologies across biologics, bone growth therapies and spinal implants. Learn more about our cervical solutions by visiting Orthofix.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy